Seer Appoints Nicolas Roelofs to its Board of Directors
14 Agosto 2024 - 3:05PM
Seer, Inc. (Nasdaq: SEER), a leading life sciences company
commercializing a disruptive new platform for proteomics, today
announced it has appointed Dr. Nicolas Roelofs to serve on its
Board of Directors.
“Nick is a fantastic addition to our board,
bringing over 35 years of broad operational and advisory experience
with leading healthcare, life science tools, and diagnostics
companies,” said Omid Farokhzad, Chair and CEO of Seer. “His
extensive experience and insights will be valuable as we advance
our mission of opening up a new gateway to the proteome.”
“I’m excited to work with the Seer team and
leverage my experience in the life science tools industry to drive
their next phase of growth,” said Dr. Roelofs. “Seer uniquely
enables deep, unbiased proteomic analysis at a scale, speed, and
robustness previously not possible, and I believe they are at the
leading edge of the expanding proteomics market. I look forward to
sharing my insights and experience to help accelerate the adoption
of the Proteograph Product Suite and transform our understanding of
the proteome.”
Dr. Roelofs previously served as the President
of the Life Sciences Group at Agilent Technologies, Group
Operations Officer for the Life Sciences Division of Bio-Rad Inc,
and Chief Operating Officer at Stratagene Inc. He has previously
served on the boards of several public and private companies
including Olink Holding AB. Dr. Roelofs currently serves as
chairman of Sengenics Corporation LLC, a board member of Velsera,
LGC Group, and an advisory board member of 908 Devices Inc.
Dr. Roelofs holds a doctorate in organic
chemistry from University of Nevada, Reno, a master’s degree in
organic chemistry from Iowa State University, and a bachelor’s
degree in chemistry, biology, and German from Simpson College.
About Seer
Seer is a life sciences company developing transformative
products that open a new gateway to the proteome. Seer’s
Proteograph Product Suite is an integrated solution that includes
proprietary engineered nanoparticles, consumables, automation
instrumentation and software to perform deep, unbiased proteomic
analysis at scale in a matter of hours. Seer designed the
Proteograph workflow to be efficient and easy to use, leveraging
widely adopted laboratory instrumentation to provide a
decentralized solution that can be incorporated by nearly any lab.
Seer’s Proteograph Product Suite is for research use only and is
not intended for diagnostic procedures. For more information,
please visit www.seer.bio.
Investor Contact:Carrie
Mendivilinvestor@seer.bio
Media Contact:Patrick Schmidtpr@seer.bio
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/d69812e6-055b-486d-9bda-37b742e0020a
Seer (NASDAQ:SEER)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Seer (NASDAQ:SEER)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024